Dr. Saba on Emerging Sequencing Strategies in Head and Neck Cancer


In Partnership With:

Nabil F. Saba, MD, FACP, discusses ​emerging sequencing ​strategies in head and neck cancer. 

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ​emerging sequencing ​strategies in head and neck cancer. 

An abundance of research regarding optimal sequencing was presented during the 2020 ASCO Virtual Scientific Program, says Saba.

KEYNOTE-048, for example, was a randomized, phase 3 study that enrolled patients with recurrent or metastatic head and neck squamous cell carcinoma. Participants were stratified 1:1:1 to receive pembrolizumab (Keytruda) monotherapy, pembrolizumab plus chemotherapy, or cetuximab (Erbitux) plus chemotherapy.

Notably, this was an important trial because it established pembrolizumab as an accepted ​frontline standard of care in this patient population, Saba concludes. 

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD